Characterisation of an antibody specific for coagulation factor VIII that enhances factor VIII activity

Thrombosis and Haemostasis

Volumn 103, Issue 1, 2010, Pages 94-102

  Takeyama, Masahiro ^a   Nogami, Keiji ^a   Matsumoto, Tomoko ^a   Soeda, Tetsuhiro ^b   Suzuki, Tsukasa ^b   Hattori, Kunihiro ^b   Shima, Midori ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

A2 epitope; Enhancing antibody; FVIII activation; Stability; Thrombin

Indexed keywords

ARGININE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8A; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BLOOD CLOTTING FACTOR 8; NEUTRALIZING ANTIBODY; THROMBIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANTIBODY SPECIFICITY; ARTICLE; BLOOD CLOTTING; CATALYSIS; CONTROLLED STUDY; HEMOPHILIA A; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; BINDING SITES, ANTIBODY; BLOOD COAGULATION; EPITOPE MAPPING; EPITOPES; FACTOR VIII; FACTOR VIIIA; FACTOR XA; KINETICS; MICE; PARTIAL THROMBOPLASTIN TIME; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; THROMBIN;

EID: 74249092254     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-05-0338     Document Type: Article

References (26)

1. Mann KG, Nesheim ME, Church WR, et al. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1-16.
2. Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312: 330-337.
3. Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII: correlation of specific cleavages by thrombin, factor Xa and activated protein C with activation and inactivation of factor VIII coagulation activity. Biochemistry 1986; 25: 505-512.
4. Fay PJ. Activation of factor VIII and mechanisms of cofactor action. Blood Rev 2004; 18: 1-15.
5. Shima M. Characterization of factor VIII inhibitors. Int J Hematol 2006; 83: 109-118.
6. Saenko EL, Shima M, Rajalakshmi KJ, et al. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 1994; 269: 11601-11605.
7. Scandella D, Gilbert GE, Shima M, et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995; 86: 1811-1819.
8. Nogami K, Shima M, Hosokawa K, et al. Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689. J Biol Chem 2000; 275: 25774-25780.
9. Nogami K, Shima M, Hosokawa K, et al. Role of factor VIII C2 domain in factor VIII binding to factor Xa. J Biol Chem 1999; 274: 31000-31007.
10. Fay PJ, Scandella D. Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa. J Biol Chem 1999; 274: 29826-29830.
11. Zhong D, Saenko EL, Shima M, et al. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood 1998; 92: 136-142.
12. Nogami K, Lapan KA, Zhou Q, et al. Identification of a factor Xa-interactive site within residues 337-372 of the factor VIII heavy chain. J Biol Chem 2004; 279: 15763-15771.
13. Mimms LT, Zampighi G, Nozaki Y, et al. Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside. Biochemistry 1981; 20: 833-840.
14. Shima M, Scandella D, Yoshioka A, et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 1993; 69: 240-246.
15. Matsumoto T, Shima M, Takeyama M, et al. The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay. J Thromb Haemost 2006; 4: 377-384.
16. Lollar P, Fay PJ, Fass DN. Factor VIII and factor VIIIa. Methods Enzymol 1993; 222: 128-143.
17. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
18. Dargaud Y, Béguin S, Lienhart A, et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93: 475-480.
19. Wakabayashi H, Varfaj F, Deangelis J, et al. Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface. Blood 2008; 112: 2761-2769.
20. Ansong C, Fay PJ. Factor VIII A3 domain residues 1954-1961 represent an A1 domain-interactive site. Biochemistry 2005; 44: 8850-8857.
21. Fay PJ, Haidaris PJ, Smudzin TM. Human factor VIIIa subunit structure. Reconstitution of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J Biol Chem 1991; 266: 8957-8962.
22. Blanco AN, Peirano AA, Grosso SH, et al. An ELISA system to detect anti-factor VIII antibodies without interference by lupus anticoagulants. Preliminary data in hemophilia A patients. Haematologica 2000; 85: 1045-1050.
23. Lacroix-Desmazes S, Moreau A, Sooryanarayana, et al. Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat Med 1999; 5: 1044-1047.
24. Kerschbaumer RJ, Riedrich K, Kral M, et al. An antibody specific for coagulation factor IX enhances the activity of the intrinsic factor X-activating complex. J Biol Chem 2004; 279: 40445-40450.
25. Nogami K, Saenko EL, Takeyama M, et al. Identification of a thrombin-interactive site within the FVIII A2 domain that is responsible for the cleavage at Arg372. Br J Haematol 2008; 140: 433-443.
26. Nogami K, Zhou Q, Myles T, et al. Exosite-interactive regions in the A1 and A2 domains of factor VIII facilitate thrombin-catalyzed cleavage of heavy chain. J Biol Chem 2005; 280: 18476-18487.